05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
(1) Drug carriers for medical use, namely, polymer-lipid matrix formulation for localized drug delivery; drug delivery formulations for medical use, namely, drug delivery agents in the form of polymer-lipid matrix for sustained delivery of drugs; drug delivery formulations for medical use, namely, drug delivery formulations in the form of powders and pastes that provide sustained release of a wide variety of pharmaceutically active agents; antibiotic delivery formulations for medical use, comprising polymer-lipid based matrix formulations for the continuous release of antibiotic drugs for medical use, namely for the prevention and treatment of infections associated with surgical procedures; drug delivery formulations for medical use, namely, drug delivery agents comprised of polymeric based particles coated with polymer-lipid matrix for sustained delivery of antibiotics; drug delivery formulations for medical use, namely, drug delivery agents comprised of polymeric based particles impregnated with polymer-lipid matrix for sustained delivery of antibiotics; drug delivery formulations for medical use, namely, drug delivery agents being mineral based particles coated with polymer-lipid matrix for sustained delivery of antibiotics; drug delivery formulations for medical use, namely, drug delivery agents being mineral based particles impregnated with polymer-lipid matrix for sustained delivery of antibiotics.
(2) Drug delivery systems for medical use, namely, surgical instruments and materials being sutures, orthopedic and dental nails, bone screws, surgical staples, medical guidewires and surgical k-wires, surgical pins, surgical sponges, metal and polymeric implants, all coated with polymer-lipid matrix for sustained drug delivery; drug delivery systems for medical use, namely, surgical instruments and materials being sutures, orthopedic and dental nails, bone screws, surgical staples, medical guidewires and surgical k-wires, surgical pins, surgical sponges, metal and polymeric implants, all impregnated with polymer-lipid matrix for sustained antibiotic drug delivery; drug delivery systems for medical use, namely, surgical instruments and materials being sutures, orthopedic and dental nails, bone screws, surgical staples, medical guidewires and surgical k-wires, surgical pins, surgical sponges, metal and polymeric implants, all coated with polymer-lipid matrix for sustained antibiotic drug delivery.
4.
COMPOSITIONS AND METHODS FOR THE TREATMENT AND PROPHYLAXIS OF SURGICAL SITE INFECTIONS
The present invention provides methods for preventing, inhibiting or treating a surgical site infection associated with a surgical operation comprising the step of applying to the surgical site a biocompatible, biodegradable substrate being impregnated and/or having its surface coated fully or partially with a matrix composition which provides local controlled and prolonged release of at least one pharmaceutically active agent at the surgical site.
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
5.
COMPOSITIONS AND METHODS FOR THE TREATMENT OF SOLID TUMORS
The present invention provides methods for treating solid tumors, reducing local tumor recurrence and tumor metastatic spreading, by administering directly into the tumor or to the tumor resection cavity a pharmaceutical composition comprising a particulate biodegradable substrate coated with a polymer-lipid based matrix which provide local sustained release of a taxane chemotherapeutic drug. The present invention further provides methods for treating chemotherapy resistant tumors.
A61K 31/495 - Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two nitrogen atoms as the only ring hetero atoms, e.g. piperazine
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Drug carriers for medical use, namely, antibiotic polymer-lipid matrix formulations for the prevention and treatment of infections associated with surgical procedures; drug delivery formulations for medical use. Drug delivery systems for medical use.
7.
Compositions and methods for the treatment and prophylaxis of surgical site infections
The present invention provides methods for preventing, inhibiting or treating a surgical site infection associated with a surgical operation comprising the step of applying to the surgical site a biocompatible, biodegradable substrate being impregnated and/or having its surface coated fully or partially with a matrix composition which provides local controlled and prolonged release of at least one pharmaceutically active agent at the surgical site.
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
A61K 45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61P 31/00 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
8.
COMPOSITIONS AND METHODS FOR THE TREATMENT OF SOLID TUMORS
The present invention provides methods for treating solid tumors, reducing local tumor recurrence and tumor metastatic spreading, by administering directly into the tumor or to the tumor resection cavity a pharmaceutical composition comprising a particulate biodegradable substrate coated with a polymer-lipid based matrix which provide local sustained release of a taxane chemotherapeutic drug. The present invention further provides methods for treating chemotherapy resistant tumors.
The present invention provides methods for treating solid tumors, reducing local tumor recurrence and tumor metastatic spreading, by administering directly into the tumor or to the tumor resection cavity a pharmaceutical composition comprising a particulate biodegradable substrate coated with a polymer-lipid based matrix which provide local sustained release of a taxane chemotherapeutic drug. The present invention further provides methods for treating chemotherapy resistant tumors.
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Drug carriers for medical use, namely, polymer-lipid matrix formulation for localized drug delivery; drug delivery formulations for medical use, namely, drug delivery agents in the form of polymer-lipid matrix for sustained drug delivery; drug delivery formulations for medical use, namely, drug delivery formulations being drug delivery agents in the form of powders and pastes that provide sustained release of the active ingredients for a wide variety of pharmaceuticals; antibiotic delivery systems comprising polymer-lipid based matrix formulation for the continuous release of antibiotic drugs for medical use, namely for the prevention and treatment of infections associated with surgical procedures; drug delivery systems for medical use, namely, drug delivery agents being polymeric based particles coated with polymer-lipid matrix for sustained antibiotic drug delivery; drug delivery systems for medical use, namely, drug delivery agents being polymeric based particles impregnated with polymer-lipid matrix for sustained antibiotic drug delivery; drug delivery systems for medical use, namely, drug delivery agents being mineral based particles coated with polymer-lipid matrix for sustained antibiotic drug delivery; drug delivery systems for medical use, namely, drug delivery agents being mineral based particles impregnated with polymer-lipid matrix for sustained antibiotic drug delivery Drug delivery systems for medical use, namely, surgical instruments and materials being sutures, orthopedic and dental nails, screws, staples, wires, pins, sponges, metal and polymeric implants, all coated with polymer-lipid matrix for sustained drug delivery; Drug delivery systems for medical use, namely, surgical instruments and materials being sutures, orthopedic and dental nails, screws, staples, wires, pins, sponges, metal and polymeric implants, all impregnated with polymer-lipid matrix for sustained antibiotic drug delivery; Drug delivery systems for medical use, namely, surgical instruments and materials being sutures, orthopedic and dental nails, screws, staples, wires, pins, sponges, metal and polymeric implants, all coated with polymer-lipid matrix for sustained antibiotic drug delivery
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Drug carriers for medical use, namely, polymer-lipid matrix formulation for localized drug delivery; drug delivery formulations for medical use, namely, drug delivery agents in the form of polymer-lipid matrix for sustained drug delivery; drug delivery formulations for medical use, namely, drug delivery formulations being drug delivery agents in the form of powders and pastes that provide sustained release of the active ingredients for a wide variety of pharmaceuticals; antibiotic delivery systems comprising polymer-lipid based matrix formulation for the continuous release of antibiotic drugs for medical use, namely for the prevention and treatment of infections associated with surgical procedures; drug delivery systems for medical use, namely, drug delivery agents being polymeric based particles coated with polymer-lipid matrix for sustained antibiotic drug delivery; drug delivery systems for medical use, namely, drug delivery agents being polymeric based particles impregnated with polymer-lipid matrix for sustained antibiotic drug delivery; drug delivery systems for medical use, namely, drug delivery agents being mineral based particles coated with polymer-lipid matrix for sustained antibiotic drug delivery; drug delivery systems for medical use, namely, drug delivery agents being mineral based particles impregnated with polymer-lipid matrix for sustained antibiotic drug delivery Drug delivery systems for medical use, namely, surgical instruments and materials being sutures, orthopedic and dental nails, screws, staples, wires, pins, sponges, metal and polymeric implants, all coated with polymer-lipid matrix for sustained drug delivery; Drug delivery systems for medical use, namely, surgical instruments and materials being sutures, orthopedic and dental nails, screws, staples, wires, pins, sponges, metal and polymeric implants, all impregnated with polymer-lipid matrix for sustained antibiotic drug delivery; Drug delivery systems for medical use, namely, surgical instruments and materials being sutures, orthopedic and dental nails, screws, staples, wires, pins, sponges, metal and polymeric implants, all coated with polymer-lipid matrix for sustained antibiotic drug delivery
05 - Pharmaceutical, veterinary and sanitary products
10 - Medical apparatus and instruments
Goods & Services
Drug carriers for medical use, namely, polymer-lipid matrix for localized drug delivery; drug delivery agents in the form of polymer-lipid matrix for sustained delivery; drug delivery formulations for medical use, namely, drug delivery formulations being drug delivery agents in the form of powders and pastes that provide sustained release of the active ingredients for a wide variety of pharmaceuticals; Drug delivery systems for medical use, namely, surgical, biomedical, orthopaedic and dental materials being drug delivery agents in the form of allogeneic, xenogeneic and synthetic bone filler particles coated with polymer-lipid matrix for sustained drug delivery release of the active ingredients for a wide variety of pharmaceuticals Drug delivery systems for medical use, namely, surgical, biomedical, orthopaedic and dental instruments and materials being sutures, orthopedic and dental nails, screws, staples, wires, pins, sponges, metal and polymeric implants, all coated with polymer-lipid matrix for sustained drug delivery
15.
Compositions and methods for the treatment and prophylaxis of surgical site infections
The present invention provides methods for preventing, inhibiting or treating a surgical site infection associated with a surgical operation comprising the step of applying to the surgical site a biocompatible, biodegradable substrate being impregnated and/or having its surface coated fully or partially with a matrix composition which provides local controlled and prolonged release of at least one pharmaceutically active agent at the surgical site.
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61K 31/685 - Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
The present invention provides compositions for extended release of an active ingredient, comprising a lipid-saturated matrix formed from a biodegradable polymer. The present invention also provides methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of an active ingredient in the body of a subject in need thereof.
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61L 27/18 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
A61L 27/58 - Materials at least partially resorbable by the body
A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
The present invention relates to pharmaceutical compositions and methods for the treatment of peri-implant diseases, in particular peri-implant disease characterized by the destruction of the crest of the alveolar bone supporting the implant. Specifically, the method comprising the step of applying to a peri-implant bone displaying crestal resorption a 5 pharmaceutical composition comprising biocompatible bone augmentation material coated with a matrix composition which provides local controlled and prolonged release of at least one pharmaceutically active agent at the bone loss site.
A61K 33/06 - Aluminium, calcium or magnesiumCompounds thereof
A61K 6/831 - Preparations for artificial teeth, for filling teeth or for capping teeth comprising non-metallic elements or compounds thereof, e.g. carbon
A61K 6/849 - Preparations for artificial teeth, for filling teeth or for capping teeth comprising inorganic cements
The present invention provides compositions for extended release of an active ingredient, comprising a lipid-saturated matrix formed from a biodegradable polymer. The present invention also provides methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of an active ingredient in the body of a subject in need thereof.
A61K 9/22 - Sustained or differential release type
A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
The present invention relates to pharmaceutical compositions and methods for the treatment of peri-implant diseases, in particular peri-implant disease characterized by the destruction of the crest of the alveolar bone supporting the implant. Specifically, the method comprising the step of applying to a peri-implant bone displaying crestal resorption a 5 pharmaceutical composition comprising biocompatible bone augmentation material coated with a matrix composition which provides local controlled and prolonged release of at least one pharmaceutically active agent at the bone loss site.
A61K 31/575 - Compounds containing cyclopenta[a]hydrophenanthrene ring systemsDerivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61P 1/02 - Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
A61P 19/08 - Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
20.
COMPOSITIONS AND METHODS FOR THE TREATMENT AND PROPHYLAXIS OF SURGICAL SITE INFECTIONS
The present invention provides methods for preventing, inhibiting or treating a surgical site infection associated with a surgical operation comprising the step of applying to the surgical site a biocompatible, biodegradable substrate being impregnated and/or having its surface coated fully or partially with a matrix composition which provides local controlled and prolonged release of at least one pharmaceutically active agent at the surgical site.
The present invention relates to pharmaceutical compositions and methods for the treatment of peri-implant diseases, in particular peri-implant disease characterized by the destruction of the crest of the alveolar bone supporting the implant. Specifically, the method comprising the step of applying to a peri-implant bone displaying crestal resorption a 5 pharmaceutical composition comprising biocompatible bone augmentation material coated with a matrix composition which provides local controlled and prolonged release of at least one pharmaceutically active agent at the bone loss site.
The present invention provides methods for preventing, inhibiting or treating a surgical site infection associated with a surgical operation comprising the step of applying to the surgical site a biocompatible, biodegradable substrate being impregnated and/or having its surface coated fully or partially with a matrix composition which provides local controlled and prolonged release of at least one pharmaceutically active agent at the surgical site.
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
A61K 47/30 - Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
The present invention relates to compositions, methods and medical devices for the treatment of bone voids and bone defects. The methods of the invention comprise the step of applying to a bone void or bone defect site a composition comprising a matrix which provides local prolonged release of at least one antibiotic agent at the bone void site.
The present invention provides compositions for extended release of one or more active ingredients, comprising a lipid-saturated matrix formed from a non-biodegradable polymer or a block-co-polymers comprising a non-biodegradable polymer and a biodegradable polymer. The present invention also provides methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of an active ingredient in the body of a subject in need thereof.
The present invention provides compositions for extended release of an active ingredient, comprising a lipid-saturated matrix formed from a biodegradable polymer. The present invention also provides methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of an active ingredient in the body of a subject in need thereof.
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61L 31/16 - Biologically active materials, e.g. therapeutic substances
A61L 27/18 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
A61L 27/54 - Biologically active materials, e.g. therapeutic substances
A61L 27/58 - Materials at least partially resorbable by the body
A61L 31/06 - Macromolecular materials obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 31/192 - Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
A61K 31/427 - Thiazoles not condensed and containing further heterocyclic rings
There are provided compositions for extended release of a nucleic acid agent, comprising a lipid-saturated matrix formed with a biodegradable polymer. Also provided are methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of the nucleic acid agent.
C12N 15/88 - Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation using microencapsulation, e.g. using liposome vesicle
The present invention relates to compositions, methods and medical devices for the treatment of bone voids and bone defects. The methods of the invention comprise the step of applying to a bone void or bone defect site a composition comprising a matrix which provides local prolonged release of at least one antibiotic agent at the bone void site.
The present invention relates to compositions, methods and medical devices for the treatment of bone voids and bone defects. The methods of the invention comprise the step of applying to a bone void or bone defect site a composition comprising a matrix which provides local prolonged release of at least one antibiotic agent at the bone void site.
A61K 47/48 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives the non-active ingredient being chemically bound to the active ingredient, e.g. polymer drug conjugates
A61K 33/06 - Aluminium, calcium or magnesiumCompounds thereof
The present invention provides compositions for controlled release of a peptidic molecule comprising a lipid-saturated matrix comprising a biocompatible polymer and a peptidic molecule associated with PEG. The present invention also provides methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of the peptidic molecule.
The present invention provides compositions for extended release of a nucleic acid agent, a biodegradable polymer. The present invention also provides methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of the nucleic acid agent.
The present invention provides compositions for extended release of one or more active ingredients, comprising a lipid-saturated matrix formed from a non-biodegradable polymer or a block-co-polymers comprising a non-biodegradable polymer and a biodegradable polymer. The present invention also provides methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of an active ingredient in the body of a subject in need thereof.
The present invention provides compositions for extended release of a nucleic acid agent, a biodegradable polymer. The present invention also provides methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of the nucleic acid agent.
A61K 47/32 - Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
A61K 48/00 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseasesGene therapy
The present invention provides compositions for extended release of a nucleic acid agent, a biodegradable polymer. The present invention also provides methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of the nucleic acid agent.
The present invention provides compositions for extended release of an active ingredient, comprising a lipid-saturated matrix formed from a biodegradable polymer. The present invention also provides methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of an active ingredient in the body of a subject in need thereof.
The present invention provides compositions for extended release of one or more active ingredients, comprising a lipid-saturated matrix formed from a non-biodegradable polymer or a block- co-polymers comprising a non-biodegradable polymer and a biodegradable polymer. The present invention also provides methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of an active ingredient in the body of a subject in need thereof.
The present invention provides compositions for extended release of one or more active ingredients, comprising a lipid-saturated matrix formed from a non-biodegradable polymer or a block- co-polymers comprising a non-biodegradable polymer and a biodegradable polymer. The present invention also provides methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of an active ingredient in the body of a subject in need thereof.
A61K 9/00 - Medicinal preparations characterised by special physical form
A61K 45/00 - Medicinal preparations containing active ingredients not provided for in groups
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
A61L 31/16 - Biologically active materials, e.g. therapeutic substances
The present invention provides compositions for extended release of an active ingredient, comprising a lipid-saturated matrix formed from a biodegradable polymer. The present invention also provides methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of an active ingredient in the body of a subject in need thereof.
A61K 47/24 - Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
A61K 47/28 - Steroids, e.g. cholesterol, bile acids or glycyrrhetinic acid
A61K 47/34 - Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
C08J 3/215 - Compounding polymers with additives, e.g. colouring in the presence of a liquid phase the polymer being premixed with a liquid phase at least one additive being also premixed with a liquid phase
C08L 67/04 - Polyesters derived from hydroxy carboxylic acids, e.g. lactones
C08L 101/16 - Compositions of unspecified macromolecular compounds the macromolecular compounds being biodegradable
The present invention provides compositions for extended release of an active ingredient, comprising a lipid-saturated matrix formed from a biodegradable polymer. The present invention also provides methods of producing the matrix compositions and methods for using the matrix compositions to provide controlled release of an active ingredient in the body of a subject in need thereof.
